06-22-2018 08:23 AM CET - Advertising, Media Consulting, Marketing Research
Print

Respiratory Syndrome (MERS) –Pharmaceutical & Healthcare disease Pipeline Analysis, H1 2018

Press release from: HTF Market Intelligence Consulting Pvt. Ltd.
Respiratory Syndrome (MERS)
Respiratory Syndrome (MERS)


HTF Market Report released a new research document of 67 pages on industry titled as 'Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as Kineta , NanoViricides, Novavax , Phelix Therapeutics LLC, Regeneron Pharmaceuticals etc The report will help you gain market insights, future trends and growth prospects for forecast period.

Request a sample report @ www.htfmarketreport.com/sample-report/1226088-middle-east...

Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2018
HTF’s latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2018, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights
HTF’s Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 8, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Buy this report @ www.htfmarketreport.com/buy-now?format=1&report=1226088

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

Autoimmune Technologies LLC
Gilead Sciences Inc
Inovio Pharmaceuticals Inc
Kineta Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
Themis Bioscience GmbH
Vaccitech Ltd

Get Customization in the Report, Enquire Now @ www.htfmarketreport.com/enquiry-before-buy/1226088-middle...

List of Figures
Introduction
Global Markets Direct Report Coverage
Middle East Respiratory Syndrome (MERS) - Overview
Middle East Respiratory Syndrome (MERS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
Autoimmune Technologies LLC
Gilead Sciences Inc
Inovio Pharmaceuticals Inc
Kineta Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
Themis Bioscience GmbH
Vaccitech Ltd
Middle East Respiratory Syndrome (MERS) - Drug Profiles
3B-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNSP-333S1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSW-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Middle East Respiratory Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/1226088-middle-east-respi...

It's vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
www.linkedin.com/company/13388569/
plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author
www.facebook.com/htfmarketintelligence/
twitter.com/htfmarketreport

This release was published on openPR.
News-ID: 1093211 • Views: 143
More releasesMore releases

You can edit or delete your press release here: